Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Samsung Makes First Foray Into U.S. Stock Market

SEOUL—Samsung will make its first entry into U.S. stock markets with an anticipated $1 billion listing of its biotechnology affiliate, according to people familiar with the matter, marking a major step in the South Korean conglomerate’s foray into a new industry outside its better-known electronics business. The listing of Samsung Bioepis Co. on the Nasdaq […]

Read More »

Applied Genetic Surges on $1 Billion+ Eye Deal With Biogen

Gainesville, Fla.-based Applied Genetic Technologies Corporation (AGTC) announced yesterday that its collaboration with Biogen, Inc. has now closed. Originally announced on July 2, 2015, the deal has met all the conditions under the Hart-Scott-Rodino Antritrust Improvements Act of 1976 and is good to go.   The deal, announced in July, was a collaboration and licensing […]

Read More »

Esperion Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval

Ann Arbor, Mich.-based Esperion Therapeutics, Inc. (ESPR), announced yesterday that the U.S. Food and Drug Administration (FDA) confirmed LDL-C as an acceptable clinical surrogate endpoint for its trial therapeutic, ETC-1002.   ETC-1002 is designed to lower cholesterol for patients who have not had success using statins, such as Pfizer Inc. (PFE)’s Lipitor. The compound is […]

Read More »

Gilead Rumored to be Eying Achillion…Again

August 17, 2015By Mark Terry, Breaking News Staff At least one analyst is again speculating that Foster City, Calif.-based Gilead Sciences, Inc. (GILD) may be ready to acquire New Haven, Conn.-based Achillion Pharmaceuticals, Inc. (ACHN). Given the company’s strong financial performance this year, many analysts believe Gilead is in the market for a strategic […]

Read More »

GSK hopes big clinical trial can breath new life into lung drug

GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result. Data from the so-called SUMMIT study, designed to show GSK’s Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years […]

Read More »

Rumors Heat Up (Again) That Pfizer Will Buy GlaxoSmithKline

Ever since Pfizer Inc. (PFE)’s $119 billion bid for UK-based AstraZeneca PLC (AZN) collapsed in May 2014, analysts have speculated on who Pfizer might buy. For several months now, heating up at the moment, those rumors have been that Pfizer might take a shot at UK-based GlaxoSmithKline (GSK).   The speculation over a Pfizer-GSK deal […]

Read More »

Juno Therapeutics Loss Widens

Juno Therapeutics Inc.’s second-quarter loss widened as the biopharmaceutical company logged higher expenses as it ramps up operations following its December initial public offering.   Research-and-development expenses surged to $60.2 million in the latest period, compared with $6.5 a year earlier, while acquisitions accounted for $77 million of spending in the latest period. Shares, down […]

Read More »

AbbVie to seek approval for potential blockbuster leukemia drug

AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential. AbbVie, which is developing the drug venetoclax with Switzerland’s Roche […]

Read More »

Shire seen having to sweeten $30 billion offer to win Baxalta

Shire Chief Executive Flemming Ornskov will need to dig deeper in his pocket if he wants to win U.S. biotech company Baxalta. The Danish doctor running the London-listed drugmaker from offices in Massachusetts is not taking the easy option with his $30 billion run at Baxalta. Rather than selling out at a premium to a […]

Read More »

What Shire-Baxalta Would Look Like if the $30 Billion Merger Goes Through

August 5, 2015By Mark Terry, Breaking News Staff After Dublin-based Shire (SHPG) publicly announced its intentions of buying Illinois-based Baxalta (BXLT) yesterday in an attempt to convince shareholders to pressure management into considering the deal, analysts are speculating on what a merged Shire and Baxalta would look like. On July 10, 2015, Shire approached […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom